Significant Ownership of Third Rock Ventures IV, L.P.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Third Rock Ventures IV, L.P. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Location
- Boston, MA
- Signature and title
- /s/ Kevin Gillis - Kevin Gillis, COO of TRV GP IV, LLC, the general partner of Third Rock Ventures GP IV, L.P., the general partner of Third Rock Ventures IV, L.P.
Large-stake snapshot
1 signal
Manager identity
2 identity fields
Follow Filing Activity
Follow Third Rock Ventures IV, L.P. and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Third Rock Ventures IV, L.P.
Significant Ownership of Third Rock Ventures IV, L.P.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | Common Stock, $0.001 par value per share | 9.3% | $179,808,372 | -$64,304,000 | 4,473,958 | -26% | Third Rock Ventures IV, L.P. | 31 Dec 2025 |
| TNGX | Tango Therapeutics, Inc. | Common Stock | 4.7% | $74,901,244 | -$17,625,000 | 6,374,574 | -19% | Third Rock Ventures IV, L.P. | 06 Feb 2026 |
Schedules 13D/G Reported by Third Rock Ventures IV, L.P.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.